Friday, June 19, 2009
Order Cancer Drugs is your source for cancer drug medication, latest cancer information, medical info, community support, question and answers about different types of cancers, health medical centers, alternative solutions, ...
Friday, June 19, 2009
Story Summary: edu614-293-3737COLUMBUS, Ohio Ohio State University cancer researchers have used computational and genomic methods to identify possible.
Thursday, June 18, 2009
Growing at a CAGR of 12.3% between 2007 and 2012, the global market for cancer drugs is expected to cross US$ 78 Billion by 2012. - Cancer vaccines and antiangiogenics will record the fastest growth rate between 2007 and 2012. ...
Thursday, June 18, 2009
THURSDAY, June 18 -- Scientists say they may be moving closer to developing a genetic test for colorectal cancer that could indicate who needs a more advance.
Thursday, June 18, 2009
Ohio State University cancer researchers have used computational and genomic methods to identify possible anti-cancer agents that may block a particular kind of tumor behavior. The agents target multiple genes associated with that ...
Thursday, June 18, 2009
“For nearly two decades, cancer drug discovery has sought agents that block a single molecular target or pathway,” he says. “Our approach identifies agents that could potentially block tumor progression by striking multiple genes that ...
Thursday, June 18, 2009
Washington, June 18 (ANI): In a breakthrough study that may lead to new cancer drugs, researchers at the University of Gothenburg have found the gate that regulates the flow of water into and out of yeast cells. ...
Thursday, June 18, 2009
The flow of water into and out from the cell may play a crucial role in several types of cancer. Scientists at the University of Gothenburg have now found the.
Thursday, June 18, 2009
Drugs that are known to cause epigenetic changes include statin cholesterol-lowering drugs, antidepressants, beta blockers used to treat high blood pressure and heart problems, anti-cancer drugs like tamoxifen and methotrexate, ...
Thursday, June 18, 2009
The company's product portfolio includes four new cancer drugs: Elacytarabine is in clinical phase II, Intravenous CP-4126 is in clinical phase II, Oral CP-4126 in phase I, and CP-4200 is in early preclinical development. ...
